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Abstract
Background: The resistance of tumour cells to apoptosis is a major contributor to the limited
effectiveness of chemotherapies. Insulin-like growth factor I (IGF-I) has potential to protect cancer
cells from variety of apoptotic challenges. This study was carried out to investigate the effect of a
novel IGF-I receptor antagonist on apoptosis in colon cancer cells.
Results: We have designed and synthesised a novel antagonist of IGF-I receptor. The effect of this
antagonist on human colon cancer cell proliferation was examined by a non-radioactive assay; the
apoptosis was revealed by determining the activities of cellular caspases3/7, 8 and 9. The apoptosis
pathways were investigated by examining the levels of pro-apoptosis proteins with Western
blotting. Following 40 hours treatment with the novel antagonist peptide, colon cancer cell Caspase
3/7 activities increased 2–7 times; Caspase 8 activities increased 2–5 times and Caspase 9 increased
1.2–1.6 times. The proliferation of cancer cell was inhibited by 14–15%. The data showed that the
antagonist induced colon cancer cell apoptosis and inhibited cancer cell proliferation. The different
changes of Caspase 3/7, 8 and 9 activities suggested that the extrinsic pathways may play a major
role in the antagonist peptide-induced apoptosis.
Conclusion: This is the first report on this novel antagonist to induce human colon cancer cell
apoptosis and inhibit cancer cell proliferation. These results suggest that IGF-I receptor antagonists
may have the potential to be developed as a novel therapy for colon cancers in the future.
Background
Worldwide, colorectal cancer accounts for almost one mil-
lion new cases and causes a half million deaths annually
[1]. In Europe colorectal cancer ranks second in frequency
of new cases in both men and women and is the second
leading killer after lung cancer [2]. Colorectal cancer is
presently treated by surgical ablation, but many colorectal
cancers are detected at a late stage when surgery cannot
cure the disease. At least 40% of patients with colorectal
cancer develop metastases; chemotherapy alone or in
combination with radiotherapy can be used as an adju-
vant therapy to surgery for more advanced disease [3].
However, these approaches are not highly effective against
disseminated colorectal cancer [4]. New therapeutic strat-
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egies are needed for treatment of advanced or metastatic
colorectal cancer.
The resistance of tumour cells to apoptosis is of major
concern in cancer therapy. It is a major contributor to the
limited effectiveness of current chemotherapeutic drugs.
Several growth factors have been identified as regulators
of cancer cell survival, and of these factors, insulin-like
growth factor I (IGF-I) has been reported to have a poten-
tial to protect a broad range of cells from a variety of apop-
tosis challenges. IGF-I receptors are present on primary
cell masses of human colon carcinomas and on colorectal
cancer cell lines [5]. Colorectal carcinomas have a 10 to
50-fold increase in the level of IGF-I and IGF-II when
compared to adjacent uninvolved colonic mucosa [6-8].
IGF-I stimulate growth of HT-29, LS411N LS513, SW480
and WiDr human colorectal carcinoma cell lines [9].
Accumulated data from laboratory experiments demon-
strate that IGF-I and IGF-II are able to stimulate the
growth of wide variety of cancer cells and to suppress
apoptosis. Therefore the IGF system has become an attrac-
tive molecular target for anticancer therapies. Inhibition
of the IGF-IR pathway, however, had not been successfully
exploited as a major anticancer therapeutic strategy due to
the lack of clinically applicable inhibitors of IGF-IR.
Although some positive results have been obtained in
recent in vivo studies using anti-IGF-IR antibodies to treat
prostate cancer [10], the adverse effects of this therapy
cannot be ruled out as it interferes with the systemic IGF
system.
IGF-I is a 70 amino acid peptide which includes A, B, C
and D domains. Functionally IGF-I has metabolic and
mitogenic actions (which include anti-apoptosis and cel-
lular survival functions). It has been shown that IGF-I reg-
ulates cellular proliferation, differentiation [11] and
apoptosis [12] of intestinal epithelium cells. IGF-I fully
protected HT-29-D4 colon carcinoma cells form apopto-
sis induced by tumour necrosis factors-α [12]. Using
hybrid molecular and chemical modifications of constitu-
ent amino acid, it has been found that D domain and a
tyrosine residue (Tyr-60) in the A domain play a decisive
role for IGF-I binding to its receptor [13-15]. In this study
we have designed and synthesised a novel antagonist of
IGF type I receptor, which is an analogue of the IGF-I D
domain (M1557 peptide). The following is a report
regarding the effect of this IGF-I D domain analogue pep-
tide on colon cancer cell apoptosis and proliferation.
Methods
IGF-I D domain analogue peptide (M1557) design and 
synthesis
The design and sequences of IGF-I D domain analogue
peptide (M1557) is shown in Figure 1. Sequences of the
peptide covered the entire IGF-I D domain plus 3 extra
amino acid residues from the A domain. It was reported
that the residual Try-60 in the A domain has a critical role
for IGF-I binding to its receptor [15], therefore we
included 3 extra amino acid residues (including Try-60) in
the N-terminal of the peptide. The peptide was synthe-
sised by Alta Bioscience (University of Birmingham) using
solid phase peptide synthesis in the sequence Y (Acm)
CAPLKPAKSA-amide. In order to avoid enzyme recogni-
tion and subsequent cleavage, the amino acids used were
all D-isomer except Cysteine (Acm). Cysteine was pro-
tected with ACM intact attached. The peptide was purified
by high-pressure liquid chromatography (HPLC). The
purity and quality of the peptide were determined and
controlled by mass spectrometer and HPLC.
Human insulin-like growth factor I (IGF-I) sequences and the relation of M1557 peptide to insulin-like growth factor I domains Figure 1
Human insulin-like growth factor I (IGF-I) sequences and the relation of M1557 peptide to insulin-like growth 
factor I domains.
GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA 
B C A D Domains 
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Reagents
Recombinant human IGF-I was purchased from Pepro-
tech EC Ltd (UK). Caspase3/7, Caspase 8 and Caspase 9
activity assay kits and CellTiter-Glo luminescent kits were
purchased from Promega (Madison, USA). Modified
Lowry protein assay kit was purchased from Pierce Bio-
technology (USA). Bax polyclonal antibodies were pur-
chased from Santa-Cruz (USA). All cell cultural mediums,
serums and antibiotics were purchased from GIBCO
(UK).
Cell lines and cultural conditions
The human colon cancer cell line (HT29) was purchased
from European Collection of Cell Cultures (ECACC) and
maintained with Growth Medium (GM, McCoy's 5A
medium containing 2 mM glutamine, 10% foetal bovine
serum and 1% penicillin and streptomycin) at 37°C with
5% CO2/95% air. Cells were used at passages 3–8 after
their receipt from the supplier.
Cancer cell apoptosis assay
Human colon cancer cells (HT-29) were seeded on white-
walled 96 well plates with McCoy's 5A medium contain-
ing 2 mM glutamine, 10% foetal bovine serum and 1%
penicillin and streptomycin at the density of 2 × 104 cells/
well. The different concentrations (0, 0.001, 0.01, 0.1, 1
and 2 μM) of M1557 peptide were included in the
medium. For the control purpose, blank reaction (GM
medium only) and positive reaction (cell with GM con-
taining Dexamethasone, a classic apoptosis inducer [16])
were also included. After 40 hours treatment, the cells
were subjected to Caspase 3/7, 8, 9 activities measurement
with Caspase-Glo assay kit (Promega, Madison USA).
Briefly, the plates containing cells were removed from the
incubator and allowed to equilibrate to room temperature
for 30 minutes. 100 μl of Caspase-Glo reagent was added
to each well, the content of well was gently mixed with a
plate shaker at 300–500 rpm for 30 seconds. The plate was
then incubated at room temperature for 2 hours. The
luminescence of each sample was measured in a plate-
reading illuminometer (Thermo Labsystems) with param-
eters of 1 minute lag time and 0.5 second/well read time.
All Caspase activities were expressed as increase fold com-
pared to untreated cells. The experiments were performed
in triplicate and repeated on two separately-initiated cul-
tures.
Establishment of cellular proliferation assay for cancer cell 
lines
In order to establish a suitable cell proliferation assay for
colon cancer cell line, human colon cancer HT-29 cells
were seeded on 96 well plate with GM (McCoy's 5A
medium containing 2 mM glutamine, 10% foetal bovine
serum and 1% penicillin and streptomycin) at densities of
1250, 2500, 5000, 10000 and 20000 cells/well. Each cell
density included 5 wells. Cells were incubated at 37°C in
5% CO2/95% air. Foetal bovine serum (FBS) has been
proven to affect the result of Alamar blue assay [17] there-
fore after 48 hours of growth, GM was removed from each
well and replaced with 200 μl of warmed fresh McCoy's
5A medium containing 2 mM glutamine and 1% penicil-
lin and streptomycin (without FBS) plus 20 μl of Alamar
Blue dye (Serotec, UK) which have been proven to be a
new rapid and simple non-radioactive assay for cellular
proliferation assessment [18]. Cells were further incu-
bated at 37°C with 5% CO2/95% air for 5 hours. The flu-
orescence was measured with excitation at 530 and
emission at 620 nm. The cellular proliferation in different
cell density was then plotted.
Validation of modified version of the Alamar Blue assay
To validated modified version of the Alamar Blue assay, a
cell viability assay was carried out using CellTiter-Glo
luminescent cell viability assay kit (Promega, Madison
USA). Human colon cancer HT-29 cells were seeded on
two parallel blank-walled 96-well plates with GM
(McCoy's 5A medium containing 2 mM glutamine, 10%
foetal bovine serum and 1% penicillin and streptomycin)
at densities of 1250, 2500, 5000, 10000 and 20000 cells/
well. The medium volume for each well was 100 μl. Cells
were incubated at 37°C in 5% CO2/95% air for 48 hours;
after incubation cells in one plate were directly subjected
to the cell viability assay. Cells in another plate were sub-
jected to the following procedures. Firstly GM was
removed from each well and replaced with 100 μl of
warmed fresh McCoy's 5A medium containing 2 mM
glutamine and 1% penicillin and streptomycin (without
FBS). Secondly cells were incubated at 37°C with 5%
CO2/95% air for further 5 hours. After incubation the
plate was subjected to the cell viability assay.
The procedures for cell viability assay for both plates were
the same. Briefly, after incubation, plates were equili-
brated to room temperature from 37°C for 30 minutes.
100 μl of CellTiter-Glo reagent (Promega, Madison USA)
was added to each well and mixed for 2 minute on orbital
shaker. The plate was incubated at room temperature for
10 minutes to stabilize luminescent signal. The lumines-
cence of each sample was measured in a plate-reading illu-
minometer (Thermo Labsystems) with parameters of 1
minute lag time and 0.5 second/well read time. The exper-
iments were performed in triplicate and repeated on two
separately-initiated cultures.
Effect of M1557 peptide on colon cancer cell growth
To evaluate the effect of M1557 peptide on colon cancer
cell proliferation, human colon cancer HT-29 cells were
seeded on a 96 well plate with McCoy's 5A medium con-
taining 2 mM glutamine, 10% foetal bovine serum and
1% penicillin and streptomycin at density of 1 × 104 cells/Molecular Cancer 2008, 7:17 http://www.molecular-cancer.com/content/7/1/17
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well for 24 hours. The medium was then replaced with the
same fresh medium plus different concentrations (0,
0.001, 0.01, 0.1 and 1 μM) of M1557 peptide. After 48
hours of exposure to the peptide, cells were then subjected
to the modified Alamar Blue assay as described previ-
ously. Percentage inhibition of cell proliferation was
determined using the following formula:
Growth inhibition (%) = Ft/Fc × 100
where Ft and Fc represent the units of fluorescence (RLU)
in the treated and the control cells respectively.
In order to prove that the inhibition of M1557 on prolif-
eration of HT-29 cells was due to the M1557 peptide
blocking IGF-I receptors specifically, cell proliferation was
also performed in serum free medium with addition of
different concentrations of IGF-I. Briefly human colon
cancer HT-29 cells were seeded onto 96 well plate with
McCoy's 5A medium containing 2 mM glutamine, 10%
foetal bovine serum and 1% penicillin and streptomycin
at density of 1 × 104 cells/well for 24 hours. The experi-
ment was performed in duplicate. For the first set of exper-
iments the medium was replaced with McCoy's 5A
medium containing 2 M glutamine and 1% penicillin-
streptomycin and different concentrations (0, 1, 10 and
100 ng/ml) of recombinant human IGF-I (Peprotech EC
Ltd, UK). For the second set, the medium was replaced
with the same medium as the first set but with addition of
2 μM of M1557 peptide in each well. After 48 hours the
cell proliferation was assessed with the method described
as previously. For cell proliferation assay all samples were
in triplicate and the experiments were repeated on two
separately-initiated cell cultures.
Protein extraction and Western Blotting
HT-29 cells were seeded in a 6 well plate either with GM
(McCoy's 5A medium containing 2 mM glutamine, 10%
foetal bovine serum and 1% penicillin and streptomycin)
or GM containing M1557 peptide (1 μM and 2 μM) at
density of 1 × 105 cells/well. After 1 week incubation, the
supernatant was removed from each well. The attached
cells were washed with PBS three times before protein
extraction. Cellular proteins were extracted with the Ripa
buffer containing protease inhibitor cocktail (Roche).
Total protein concentration in the samples was deter-
mined using a modified Lowry protein assay kit (Pierce
Biotechnology, USA). 20 μg of total protein (10μl in vol-
ume) were mixed with 10 μl of laemmi sample buffer con-
taining 4% SDS, 20% glycerol, 10% 2-mercaptoethanol,
0.004% bromphenol blue and 0.125 M tris HCl, pH
approx. 6.8 (Sigma, UK). The samples were then dena-
tured by heating at 95°C for 5 minutes. Sodium dodecyl
sulphate – polyacrylamide gel electrophoresis (SDS-
PAGE) was used to separate the proteins, which were then
electro-blotted on to polyvinylidene fluoride (PVDF)
membrane (Bio-Rad, USA). The membrane was blocked
with 5% milk in PBS (Marvel semi skimmed milk pow-
der) and incubated with rabbit anti-human Bax polyclo-
nal antibody (Santa-Cruz, USA) at 1/200 dilution
followed by incubation with anti-rabbit IgG antibody
conjugated with horse radish peroxidase (Dako, UK) at 1/
2000 dilution. Each membrane was illuminated with
Super Signal West Dura extended duration Substrate
(Pierce, USA) and exposed to X-ray film for 10 seconds
(Fuji, Japan). The X-ray films were scanned and the den-
sity of the protein bands were analysed with Bio-Rad den-
sitometry software (Molecular Analyst, windows software
for Bio-Rad image analysis system version 1.5, USA).
Statistical Analysis
All data have been examined and followed a normal dis-
tribution. All results were expressed as mean ± SM. One
way ANOVA (Prism version 4 2004 edition, USA) with
multiple comparison test was used for statistical analysis
and P < 0.05 is considered as significant and indicated as
*; P < 0.01 is considered as higher significance and indi-
cated as **. P > 0.05 is considered as not significant and
marked as NS.
Results
M1557 peptide induced colon cancer cells apoptosis
Following 40 hours incubation with M1557 peptide, cas-
pase 3/7 (cysteine aspartic acid-specific protease) activi-
ties in colon cancer (HT-29) cells increased 2–7 fold over
the dose range compared to the untreated control cancer
cells. It is worthwhile to note that the M1557 peptide
increased caspase 3/7 activities in a dose response manner
with significant effects at 0.1 μM onward concentrations
(P < 0.0001; Figure 2A). It has been recognized that cas-
pase 3/7 activation is a central initiator and executioner of
apoptosis in mammalian cells. Hence, M1557 treatment
significantly increased cancer cell apoptosis.
It has been known that caspase 3/7 is activated by active
caspase 8 or 9. We, therefore, also measured caspase 8,
and 9 activities. The results showed that M1557 peptide
increased caspase 8 activities 2–5 times over the dose
range and the increase was also in a dose response manner
with significant effects from 0.1 μM onward concentra-
tions (P < 0.0001, Figure 2B). Caspase 8 activation is the
step immediately following death-inducing signalling
complex (DISC) formation. The latter is the part of extrin-
sic apoptosis pathway which involved death ligands
bound to death receptors. The M1557 peptide also
increased caspase 9 activities. This increase is again in a
dose response manner with significant effects from 1 μM
onward concentrations (P < 0.05, Figure 2C). However, it
is interesting to note that M1557 peptide induced caspase
9 activities on a much smaller scale (1.2–1.6 times) com-Molecular Cancer 2008, 7:17 http://www.molecular-cancer.com/content/7/1/17
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Following treatment by M1557 peptide for 40 hours, human colon cancer cell (HT-29) caspase3/7 (A), 8(B) and 9 (C) activities  increased in a dose response manner Figure 2
Following treatment by M1557 peptide for 40 hours, human colon cancer cell (HT-29) caspase3/7 (A), 8(B) and 
9 (C) activities increased in a dose response manner. Caspase 3/7 activities in treated cancer cells increased 2–7 times 
compared to the untreated control cancer cells with significant effects at dose of 0.1 μM onward concentrations (P < 0.001). 
Caspase 8 activities in treated cancer cells also increased 2–5 times compared to the untreated control cancer cells, with signif-
icant effects at 0.1 μM onward concentrations (P < 0.001). Caspase 9 activities in treated cancer cells increased in a small scale 
(1.6 times), with significant effects at the higher concentrations (1 μM onward; P < 0.05) compared to caspase 3/7 and 8. Signif-
icance value: * P < 0.05; ** P < 0.001.
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pared to caspase 3/7 and 8. Caspase 9 activation is a part
of intrinsic apoptosis pathways which involves cyto-
chrome c release from the mitochondria [19] and is called
mitochondria-mediated apoptosis. M1557 peptide
increased caspase 3/7 and 8 activities by a large scale (2–7
fold for caspase 3/7, 2–5 fold for caspase 8). It appears
that M1557 peptide induce cancer cells death mainly via
the extrinsic apoptosis pathway. The intrinsic apoptosis
pathway cannot be ruled out as M1557 peptide also
increased caspase 9 activities by a smaller scale (1.2–1.6
folds) with higher concentrations.
Establishment and validation of cellular proliferation assay 
for cancer cells
In order to assess cancer cell growth, a rapid and simple
cellular proliferation assay is needed. Alamar Blue (Sero-
tec, UK) has been proven to be a new rapid and simple
non-radioactive dye for cellular proliferation assessment
[18], but serum proteins and FBS used in cell culture were
proven to interfere with Alamar Blue assay [17]. To avoid
this interference, we have modified the assay by replacing
GM medium (containing FBS) with the fresh warmed
serum-free medium at the end of the treatment. Using this
modified Alamar Blue assay to assess the different densi-
ties (1250, 2500, 5000, 10000 and 20000 cells/well) of
HT-29 cancer cells, the results are shown in Figure 3A. In
Figure 3A it is shown that the fluorescence (indicates of
cell numbers) increased along with the increases of cell
densities of 1250–10000 cells/well. This indicated that
the fluorescence reading may define the true cell numbers
in these cell densities. It should also be stated that the flu-
orescence decreased at 20000 cells/well density. The
decrease was not statistically significant when comparing
the reading at 20000 cell/well with that at 10000 cells/
well (P > 0.05).
In order to validate the modified version of Alamar Blue
assay and also to find whether the fluorescence drop at
20000 cells/well is a feature of the assay or cellular prolif-
eration itself, cell viability assays were carried out. In cell
viability assays, two parallel procedures were performed
simultaneously. One procedure was the modified proce-
dure similar to that in the modified Alamar Blue assay.
Another procedure was a non modified procedure. At the
end of two procedures, the cell numbers were assessed
using the CellTiter-Glo luminescent cell viability assay.
CellTiter-Glo luminescent cell viability assay is a homoge-
neous method of determining the number of viable cells
in culture based on quantitation of the ATP present,
which signals the presence of metabolically active cells.
This method has been proven to be a accurate assay for
cell proliferation and cytotoxicity [20]. The results of the
parallel assays are shown in Figure 3B (modified proce-
dure) and C (no modified procedure). In Figure 3B and
3C it can be seen that luminescence (indicator of the
number of viable cells) increased along with the increases
of cell densities between 1250–10000 cells/well for both
procedures (modified and not modified). It is interesting
to note that luminescence at 20000 cell/well decreased in
both procedures, although the decreases were not statisti-
cally significant compared to that at 10000 cell/well den-
sity (P > 0.05). The similarity of results from both
modified and not modified procedures indicated that the
modified proliferation assay has not altered the prolifera-
tion of cells. The similar reading patterns among all three
assays have also proven that the modified Alamar Blue
assay is a reliable proliferation assessment for cancer cells.
The fact that the readings seen at 20000 cells/well
decreased in all three assays indicated that the drop in flu-
orescence or luminescence seen at 20000 cells/well was
due to the cellular proliferation itself. The reasons for this
drop may due to the facts that the high rate of cancer cell
proliferation, plus the high starting density of cells will
consume essential nutrients rapidly. A previous report
similarly showed that nutritional deficiency caused
human lung cancer cell arrest [21].
M1557 peptide inhibits colon cancer cell proliferation
Following 48 hour treatment with M1557 peptide, the
proliferation of colon cancer cells was inhibited by
14–15% over the dose range of the peptide used in these
studies. This inhibition showed a tendency towards a dose
response relationship with significant effects from 0.01
μM onward concentrations (P < 0.01, Figure 4A).
In order to prove that the M1557 peptide inhibition was
due to interference with IGF-I signalling, recombinant
human IGF-I peptide was included in serum-free
medium, which normally would yield an increase in
tumour cell proliferation. The results showed that IGF-I
indeed increased cancer cell proliferation in a dose
response manner (Figure 4B). However when 2 μM of
M1557 peptide was additionally included in all samples
in a parallel experiment in which different dose of IGF-I
peptide were used, the IGF-I enhanced proliferation
response curves vanished (Figure 4C). All of these data
indicated that M1557 peptide can inhibit HT-29 cell pro-
liferation, and that this inhibition is likely to be due to its
blockage of IGF-I signalling.
M1557 increased the level of pro-apoptosis protein Bax
After 1 week's exposure to M1557 peptide, the level of Bax
protein increased in M1557 treated cancer cells compared
to untreated cells (P < 0.05 Figure 5A, C). Apoptosis is
influenced by various intracellular proteins and enzymes.
One important protein which influences apoptosis is
Bcl2-associated X protein (Bax). Bax has been shown to
promote apoptosis. The higher level of Bax in the M1557
peptide treated cancer cells indicates that M1557
increased apoptosis via Bax expression. Figure 5B showedMolecular Cancer 2008, 7:17 http://www.molecular-cancer.com/content/7/1/17
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HT-29 cellular proliferation was assessed at different cell densities (1250, 2500, 5000, 10000 and 20000 cells/well) with a mod- ified Alamar Blue assay (A) Figure 3
HT-29 cellular proliferation was assessed at different cell densities (1250, 2500, 5000, 10000 and 20000 cells/
well) with a modified Alamar Blue assay (A). The increases of fluorescence at densities of 1250–10000 cells/well indi-
cated the fluorescence readings designate the true cell number at these cell densities. The fluorescence at 20000 cells/well 
tended to decrease compared to that at 10000 cells/well, but the decrease was not statistically significant (P > 0.05, NS). To 
validate the modified version of Alamar Blue assay and to find whether the fluorescence drop at 20000 cells/well was a feature 
of the assay or cellular proliferation itself, two parallel procedures were performed simultaneously. One procedure (B) was the 
modified procedure similar to that in the modified Alamar Blue assay. Another procedure (C) was no modified procedure. The 
same range of cell densities (1250, 2500, 5000, 10000 and 20000 cells/well) were used in both procedures. At the end of two 
procedures, the cell numbers were assessed using CellTiter-Glo luminescent cell viability assay. Luminescence increased along 
with the increases of cell densities at 1250–10000 cells/well for both modified (B) and no modified (C) procedures. Lumines-
cence at 20000 cell/well tended to decrease in both procedures, although the decreases were not statistically significant com-
pared to that at 10000 cell/well density (P > 0.05; NS). Significance value: * P <0.05; ** P < 0.001; NS P > 0.05.
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After treating with M1557 peptide for 48 hours, cancer cell proliferation was inhibited by about 15% with significant effects at  doses of 0.01 μM onward Figure 4
After treating with M1557 peptide for 48 hours, cancer cell proliferation was inhibited by about 15% with sig-
nificant effects at doses of 0.01 μM onward. Again, this inhibition was in a dose responsive manner (A). To detect 
whether cellular proliferation inhibition was the result of interference with IGF-I signalling, two further experiments were per-
formed with serum free medium. In the first set of experiments cells were treated with different concentrations of recom-
binant human IGF-I and it can be seen that IGF-I increased cancer cell proliferation in serum free medium. The increase was in 
a dose responsive manner (B). In the second set, cells were also treated the same as in the first set of experiments, but also 
with addition of 2 μM M1557 peptide in all samples. It can be seen that with M1577 inclusion, the IGF-I enhancing- proliferation 
dose response curve vanished (C). Significance value: * P < 0.05; ** P < 0.001.
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the level of β-actin in each sample which was detected by
a polyclonal anti-actin antibody (Sigma, UK). β-actin was
used as internal standard to ensure the equal amounts of
protein was loaded.
Discussion
More than a decade ago it was hypothesized that cells with
accelerated rate of proliferation are more liable to lead to
the development of cancer [22]. A number of epidemio-
logic studies have shown that high levels of IGF-I are asso-
ciated with increased risk for several common cancers,
including those of breast [23], prostate [24], lung [25] and
colorectal cancers [26]. Functionally, IGF-I not only stim-
ulates cell proliferation but also inhibits cell apoptosis.
Based on the IGF-I structure, we designed and synthesised
a novel IGF-I receptor antagonist, M1557 peptide. We
tested the M1557 peptide on human colon cancer (HT-
29) cell apoptosis and proliferation. The results showed
that this IGF-I D domain analogue increased cancer cell
apoptosis, and in parallel inhibited cell proliferation. This
action appeared to be a result of interfering with IGF-I sig-
nalling.
There are several potential interventions in the IGF- I sig-
nalling pathway such as application of inhibitory anti-
bodies [10,27], anti-sense RNA constructs [28,29] and
IGF-I analogue peptides [30,31]. IGF-I D domain has
been proven to be an active site for IGF-I binding to its
receptors [13,14], we therefore chose to synthesis a D
domain analogue peptide. Although previous studies
[30,31] have targeted the IGF-I C terminal, subsequent
research using the same peptide [32,33] has provided
uncertain information. In those reports two different pep-
tides (one peptide was a partial analogue of IGF-I C termi-
nal, while another has reversed sequences compared to
the first one, but both peptides were named as JB3) were
found to inhibit early renal tissue growth in diabetic and
uninephrectomized rats but did not inhibit renal fibrosis,
in which IGF-I is also involved [32,33].
The accumulated data from multiple systems have shown
that IGF-I exerts a strong anti-apoptosis action on various
cancer cells. Few studies have defined the putative mecha-
nism by which the apoptosis process may be inhibited by
IGF-I [34]. Apoptosis may proceed in two pathways: the
intrinsic pathway and the extrinsic pathway. In the intrin-
sic pathway, stimulators such as stress, DNA damage or
chemotherapy cause release of cytochrome c from mito-
chondria which consequently activate caspase-9 and cas-
pase-3. The latter then triggers the apoptosis. The extrinsic
pathway is caused by the direct interaction between so
called "death ligands" and "death receptors", in which
caspase-8 is activated. In M1557 peptide-treated cells, the
caspase-8 activities were 2–5 times higher; caspase 3/7
were 2–7 times higher than untreated cells. In contrast,
the caspase-9 activities increased by a relatively small scale
(1.6 times) in the treated cells compared to the untreated
cells. This suggested that the extrinsic apoptosis pathway
may play the major role in the M1557 peptide-induced
apoptosis in colon cancer cells, but the role of intrinsic
apoptosis pathway cannot be completely ruled out. Fur-
ther studies are needed to address this point.
It has been recognized that the combination of mitogenic
and anti-apoptotic effects has a profound impact on
tumour growth [35]. In our experiments, we found
M1557 peptide treatment increased cancer cell apoptosis
and inhibited cancer cell proliferation. Previous studies
[30,31,36] also found that serum free-medium induced
normal and malignant cells to undergo apoptosis and that
addition IGF-I prevented the actuation of apoptosis. These
findings suggested that blockade of the IGF-I receptor
inhibited cell proliferation, perhaps as a result of the com-
bination of anti-mitogenic and pro- apoptotic effects.
Western blotting was used to detect pro-apoptosis Bcl2- associated X protein (Bax) in M1557 peptide treated and  untreated cells (A) Figure 5
Western blotting was used to detect pro-apoptosis 
Bcl2-associated X protein (Bax) in M1557 peptide 
treated and untreated cells (A). After treatment with 
M1557 peptide at 2 μM and 5 μM concentrations, the level of 
Bax increased significantly compared to that in the untreated 
cells (P < 0.01) (C). (B) The level of β-actin in each sample 
was detected by a polyclonal anti-actin antibody (Sigma, UK). 
β-actin was used as internal standard to ensure the equal 
amounts of protein was loaded.
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Conclusion
Treating human colon cancer cells with a novel IGF-I D
domain analogue (M1557 peptide) increased cancer cell
apoptosis and inhibited cancer cell proliferation. Further
examination of different caspase activities suggests that
the extrinsic apoptosis pathways may play the major role
in M1557 peptide-induced apoptosis in colon cancer
cells. These results suggest that specific IGF-I receptor
antagonists may have the potential to be developed as a
novel therapy for colon cancers in the future.
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